Celyad Oncology SA (EBR:CYAD)
Belgium · Delayed Price · Currency is EUR 0.3110
-0.0080 (-2.51%)
Apr 30, 2026, 4:00 PM CET
Celyad Oncology Revenue
In the year 2025, Celyad Oncology had annual revenue of 21.00K EUR, down -88.71%. Celyad Oncology had revenue of 7.00K in the half year ending December 31, 2025, a decrease of -87.93%.
Revenue
21.00K
Revenue Growth
-88.71%
P/S Ratio
662.90
Revenue / Employee
4.20K
Employees
5
Market Cap
13.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.00K | -165.00K | -88.71% |
| Dec 31, 2024 | 186.00K | 84.00K | 82.35% |
| Dec 31, 2023 | 102.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UCB SA | 7.74B |
| argenx SE | 3.61B |
| European Medical Solutions | 52.80M |
| Hyloris Pharmaceuticals | 8.83M |
| Onward Medical | 5.41M |
| Financière de Tubize | 13.26K |
| Oxurion NV | 2.00K |
| BioSenic | -2.39M |
Celyad Oncology News
- 2 years ago - Celyad Oncology Earnings Call Transcript: H1 2023 - Transcripts
- 3 years ago - Celyad Oncology Earnings Call Transcript: H2 2022 - Transcripts
- 4 years ago - Celyad Oncology Earnings Call Transcript: H1 2022 - Transcripts